Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group PR.7 -- A Phase III Randomized Trial Comparing Intermittent versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer

The results of the study show that intermittent androgen deprivation was noninferior to continuous therapy with respect to overall survival. Additionally, some quality of life factors, including physical function, fatigue, urinary problems, hot flashes, libido, and erectile function, improved with intermittent therapy.

The results of the trial were presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting and was selected to be included in the Best of ASCO. The final results were published in the September 6, 2012 issue of the New England Journal of Medicine.

Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. N Engl J Med 367: 895-903, 2012.

http://dx.doi.org/10.1056/NEJMoa1201546

An associated press release, issued by the Canadian Cancer Society, is posted here ... http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2012/Drug%20holiday.aspx?sc_lang=en

____________________________________________

Canadian Cancer Trials Group IND.189 -- A Phase II Study of Interlukin-21 (Il-21) in Patients with Metastatic or Recurrent Malignant Melanoma

This was a multi-centre phase II study of patients with metastatic melanoma that evaluated the efficacy, toxicity, progression-free survival, immunogenicity, and biomarker profile of interleukin-21 (IL-21). The results showed the overall response rate to IL-21 was 22.5% for first-line metastatic melanoma and warrants further investigation. Additionally, the favourable progression free survival and overall survival data suggest that this is an active agent in comparison to both historical Canadian Cancer Trials Group data and data from meta-analysis of Cooperative Group phase II trials.

Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, Kamel-Reid S, Tron V, Chen BE, Hunder NN, Hagerman L, Walsh W, Eisenhauer EA. Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study (ONLINE). J Clin Oncol 2012.

http://jco.ascopubs.org/content/early/2012/08/20/JCO.2011.40.0655.abstract